Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Dupixent® Gains CHMP Nod for Eosinophilic Esophagitis in Young Children
Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of IL-4 and IL-13 for treating eosinophilic esophagitis.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
September 20, 2024
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Dupixent® Approved for Children 1 Year and Older with EoE
Details : Dupixent (dupilumab) is a monoclonal antibody that inhibits IL-4 and IL-13 signaling, approved for children 1+ with eosinophilic esophagitis, and is not immunosuppressive.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
January 25, 2024
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13), and US FDA has accepted for Priority Review the sBLA for the treatment of children aged 1 to 11 years with eosin...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab), which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Pha...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
December 16, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab) is administered as an injection under the skin (subcutaneous injection) at different injection sites. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat EoE in the United States.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
Details : Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
May 22, 2020
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable